Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
132.4 SAR | +1.07% | +0.76% | +15.30% |
09/05 | Tadawul Shares Plunge Thursday as Saudi Arabia’s March Industrial Output Falls | MT |
09/05 | Jamjoom Pharmaceuticals Posts Higher Q1 Net Profit, Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.30% | 244.49Cr | - | ||
+15.85% | 4.26TCr | B- | ||
+18.28% | 2.1TCr | B+ | ||
+17.44% | 1.49TCr | - | ||
+17.68% | 1.45TCr | B+ | ||
+48.57% | 1.26TCr | B | ||
-0.05% | 678.76Cr | - | - | |
-12.56% | 657Cr | B+ | ||
-8.87% | 572.55Cr | - | - | |
+14.28% | 562.47Cr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4015 Stock
- Ratings Jamjoom Pharmaceuticals Factory Company